Furthermore, the efficacy of trastuzumab in HER2+ breast cancer patients was diminished following antibiotic use, coinciding with reductions in beneficial gut taxa such as Lachnospiraceae, Prevotellaceae, and Coriobacteriaceae [83]. This evidence concerns the gene ERBB2 and breast carcinoma.